Recce Pharmaceuticals
ASX:RCESydney, Australia· Est.
Recce creates synthetic polymer anti‑infectives to combat multidrug‑resistant bacteria and viruses.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Recce creates synthetic polymer anti‑infectives to combat multidrug‑resistant bacteria and viruses.
AntibacterialAntiviralInfectious Diseases
Technology Platform
Synthetic polymer anti‑infectives with a universal mechanism of action that remains potent despite repeated exposure, designed to overcome bacterial and viral resistance.
Opportunities
Successful Phase III data could unlock fast‑track FDA approval and capture a large market for multidrug‑resistant infection treatments, especially in hospital settings.
Risk Factors
High clinical development risk, reliance on external funding, and competition from other novel antibiotic platforms could delay commercialization.
Competitive Landscape
Recce’s synthetic polymer approach differentiates it from traditional small‑molecule antibiotics and biologics, offering a novel resistance‑bypass mechanism that may provide a competitive edge in the anti‑infective market.